Novartis and Pfizer sign clinical development agreement
Swiss pharmaceutical company Novartis has partnered with Pfizer, its American rival, in efforts to advance the treatment of non-alcoholic steatohepatitis (NASH).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
14 May 2026 Isomorphic Labs said the funding round, led by venture firm Thrive Capital, would be used to further its drug design engine and support hiring targets.
14 May 2026 The agreement is the latest in a string of major deals between Hengrui and multinational drugmakers, and will see the parties jointly develop assets while licensing others.
